Komori
Share Issuance and Disposal4582SymBio Pharmaceuticals LimitedPharmaceuticals

Notice Regarding Completion of the Early Redemption of the 1st Series Unsecured Straight Bonds

The remaining ¥227.5 million of the First Series Unsecured Straight Bonds issued on 26 August 2025 was redeemed early, bringing the outstanding balance to zero as of 7 July 2026.

Worth reading
38Recurring
Scored from 3 of 5 sections
Direction
Neutral
Direction inferred from the company’s description.
Scale
227500000
¥
Wording
Definitive
How definitive the wording is.

Details of issuance or disposal

Early redemption of the First Series Unsecured Straight Bonds

Intended allottee
EVO FUND
Payment date
26 August 2025
Most recent equity financing
Issued on 26 August 2025; First Series Unsecured Straight Bonds; total issue amount of ¥1,235 million
Details of issuance or disposal
ItemDetails
Type of issuance or disposalEarly redemption of the First Series Unsecured Straight Bonds
Payment date26 August 2025
Intended allotteeEVO FUND
Most recent equity financingIssued on 26 August 2025; First Series Unsecured Straight Bonds; total issue amount of ¥1,235 million
Items this document does not state (24)
Number of shares to be issued or disposed ofIssue price and disposal priceTotal issue valueAmount of funds to be raisedEstimated issuance expensesSpecific use of fundsIntended allottee's holding policyDilution RateTotal number of issued sharesBasis for determining the amount to be paidExercise priceExercise periodNumber of Stock Acquisition RightsTransfer restriction periodConditions for lifting transfer restrictionsReason for acquisition without considerationCategories and Number of Persons CoveredTotal Stock-Based CompensationUnderwriter / lead underwriterOverallotmentStock Split RatioProcedures under the Corporate Code of ConductMajor shareholders after the offeringImpact on Business Performance

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

Part of the cash paid in connection with the exercise of the 66th Series Stock Acquisition Rights was used for the early redemption.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice Regarding Completion of the Early Redemption of the 1st Series Unsecured Straight Bonds | SymBio Pharmaceuticals Limited (4582) timely disclosure | Komori